Novartis and Gen-Probe Agree to Extend and Expand Blood Screening Collaboration

Companies will work together to protect the world's supply of donated blood from infectious diseases until 2025

30-Jan-2009 - Chiron, a Novartis business, announced that it has agreed to extend and expand its blood screening collaboration with Gen-Probe until 2025. The companies will continue to work together to develop and commercialize molecular technologies that safeguard the world's donated blood supply. The ...

Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

18-Sep-2007 - Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was announced ...

Crucell Announces Product Approval in Korea for Quinvaxem Vaccine

28-Mar-2006 - Crucell N.V. announced today that the Korea Food and Drug Administration (KFDA) has awarded licensure to Quinvaxem(TM), a fully liquid pentavalent vaccine to be produced by Crucell in Korea. Quinvaxem(TM) was co-developed with Chiron Corporation, which provides four of the five components as ...

Novartis receives US regulatory approval to acquire Chiron

08-Dec-2005 - Novartis announced that it has received US regulatory approval to acquire the remaining 58% stake in the US pharmaceutical company Chiron Corporation that it does not currently own. Novartis reaffirms that it expects to complete the acquisition of Chiron in the first half of 2006, subject to ...

Chiron and XOMA announce initiation of phase I clinical trial fpr CHIR-12.12 in multiple myeloma

Second clinical trial evaluating oncology drug candidate begins

18-Oct-2005 - Chiron Corporation and XOMA Ltd. announced the initiation of a second clinical trial of CHIR-12.12, a novel, fully human, antagonist antibody that targets the CD40 antigen. The Phase I trial is for patients with multiple myeloma, a type of cancer that is associated with expression of the CD40 ...

Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron

18-Aug-2005 - Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6® cell line for use in the manufacturing of Chiron's ...

Chiron Acquires Prion Solutions Inc.

Agreement Enhances Company's Commitment to Safeguard the Blood Supply

01-Sep-2004 - Chiron Corporation announced that it had acquired Prion Solutions Inc., a privately held company based in La Jolla, Calif., focused on research into variant Creutzfeldt-Jakob disease (vCJD) and other prion-related diseases. Financial terms of the acquisition were not disclosed. "At Chiron we ...

Chiron Acquires Sagres Discovery

Acquisition Deepens Quality of Chiron's R&D Pipeline

07-Jul-2004 - Chiron Corporation and Sagres Discovery announced that Chiron has acquired Sagres. Sagres, a privately held company headquartered in Davis, Calif., focuses on the discovery and validation of targets with potential application to the development of cancer therapeutics. Financial terms of the ...

Chiron and XOMA Form Collaboration For Development and Commercialization Of Therapeutic Antibodies For Cancer

Agreement Leverages Companies' Strengths in Oncology, Antibody Discovery and Product Development

02-Mar-2004 - EMERYVILLE, Calif., and BERKELEY, Calif. Chiron Corporation and XOMA Ltd. announced a worldwide, exclusive, multi-product, collaborative agreement for the development and commercialization of antibody products for the treatment of cancer. Under the terms of the agreement, the companies will ...

Chiron Grants Nonexclusive HCV License to Boehringer Ingelheim

18-Dec-2003 - Chiron Corporation announced that it has granted to Boehringer Ingelheim International GmbH a nonexclusive license for the research, development and commercialization of small molecule therapeutics against hepatitis C virus (HCV) drug targets. Under the terms of the agreement, Boehringer ...